Viatris Inc (VTRS) |
|
15.22 0.2 (1.33%)
|
01-16 05:18 |
|
Open: |
14.902 |
Pre. Close: |
15.02 |
|
High:
|
15.255 |
Low:
|
14.8604 |
|
Volume:
|
5,773,965 |
Market Cap:
|
18,407M |
|
|
|
|
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
15.268 - 15.343 |
15.343 - 15.419 |
|
Low:
|
14.684 - 14.761 |
14.761 - 14.84 |
|
Close:
|
15.094 - 15.218 |
15.218 - 15.344 |
|
Technical analysis |
as of: 2022-01-15 8:50:44 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 17.92 One year: 20.93 |
| Support: |
Support1: 13.52 Support2: 12.40 |
| Resistance: |
Resistance1: 15.34 Resistance2: 17.92 |
| Pivot: |
14.40 |
| Moving Average: |
MA(5): 15.15 MA(20): 14.09
MA(100): 13.65 MA(250): 14.38  |
| MACD: |
MACD(12,26): 0.56 Signal(9): 0.43 |
| Stochastic oscillator: |
%K(14,3): 90.27 %D(3): 93.24 |
| RSI: |
RSI(14): 74.48 |
| 52-week: |
High: 18.68 Low: 11.96 Change(%): -12.1 |
| Average Vol(K): |
3-Month: 1044296 10-Days: 1003908 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.VTRS has closed below upper band by 18.3%. Bollinger Bands are 77.7% wider than normal. The large width of the bands suggest high volatility as compared to VTRS's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 11 Jan 2022
Viatris: Prepare For Takeoff - Seeking Alpha
Thu, 06 Jan 2022
Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend - Yahoo Finance
Tue, 04 Jan 2022
TWTR: 4 Stocks in the S&P 500 Wall Street Predicts Will Rally by More Than 20% in 2022 - StockNews.com
Mon, 03 Jan 2022
Bullish Two Hundred Day Moving Average Cross - VTRS - Nasdaq
Wed, 29 Dec 2021
Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations - Yahoo Finance
Thu, 23 Dec 2021
Interesting VTRS Put And Call Options For February 2022 - Nasdaq
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. (M) |
1,210 |
| Shares Float (M) |
1,210 |
|
% Held by Insiders
|
0.25 |
|
% Held by Institutions
|
75.18 |
|
Shares Short (K)
|
24,810 |
|
Shares Short P. Month (K)
|
28,450 |
Stock Financials |
|
EPS
|
-1.720 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
17.480 |
|
Profit Margin
|
-11.19 |
|
Operating Margin
|
13.26 |
|
Return on Assets (ttm)
|
3.3 |
|
Return on Equity (ttm)
|
-11.4 |
|
Qtrly Rev. Growth
|
52.6 |
|
Gross Profit (p.s.)
|
3.950 |
|
Sales Per Share
|
14.190 |
|
EBITDA (p.s.)
|
5.504 |
|
Qtrly Earnings Growth
|
67.70 |
|
Operating Cash Flow (M)
|
2,530 |
|
Levered Free Cash Flow (M)
|
3,320 |
Stock Valuations |
|
PE Ratio
|
-8.85 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.87 |
|
Price to Sales
|
1.07 |
|
Price to Cash Flow
|
7.28 |
Stock Dividends |
|
Dividend
|
0.330 |
|
Forward Dividend
|
0.440 |
|
Dividend Yield
|
0.02 |
|
Dividend Pay Date
|
2021-12-15 |
|
Ex-Dividend Date
|
2021-11-21 |
|
7 Binary Options
|
|
Your Ad Here
|
|
